Vitamin D as immunomodulatory therapy for kidney transplantation

Transplantation

Volumn 74, Issue 8, 2002, Pages 1204-1206

  Becker, Bryan N ^a   Hullett, Debra A ^a   O'Herrin, Jacquelyn K ^a   Malin, Gretchen ^a   Sollinger, Hans W ^a   DeLuca, Hector ^a  

^a B 3063 UW Nephrology ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; CALCITRIOL DERIVATIVE; CYCLOSPORIN A; CYTOKINE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RETINOID X RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; VITAMIN D RECEPTOR;

ANIMAL MODEL; CADAVER KIDNEY; CLINICAL ARTICLE; GRAFT REJECTION; HUMAN; HYPERCALCEMIA; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT REJECTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; SHORT SURVEY;

EID: 0037184325     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200210270-00030     Document Type: Short Survey

References (34)

1. Brown AJ, Dusso A, Slatopolsky E. Vitamin D. Am J Physiol 1999; 277: F157.
2. Lemire JM. Immunomodulatory actions of 1, 25-dihydroxyvitamin D3. J Steroid Biochem Mol Biol 1995; 53: 599.
3. Lemire JM, Adams JS, Sakai R, et al. 1 alpha, 25-dihydroxyvitamin D3 suppresses proliferation and immunoglobulin production by normal human peripheral blood mononuclear cells. J Clin Invest 1984; 74: 657.
4. Tsoukas CD, Watry D, Escobar SS, et al. Inhibition of interleukin-1 production by 1, 25-dihydroxyvitamin D3. J Clin Endocrinol Metab 1989; 69: 127.
5. Rigby WF, Denome S, Fanger MW. Regulation of lymphokine production and human T lymphocyte activation by 1, 25-dihydroxyvitamin D3. Specific inhibition at the level of messenger RNA. J Clin Invest 1987; 79: 1659.
6. Boonstra A, Barrat FJ, Crain C, et al. 1 alpha, 25-dihydroxyvitamin d3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells. J Immunol 2001; 167: 4974.
7. D'Ambrosio D, Cippitelli M, Cocciolo MG, et al. Inhibition of IL-12 production by 1, 25-dihydroxyvitamin D3. Involvement of NF-kappaB down-regulation in transcriptional repression of the p40 gene. J Clin Invest 1998; 101: 252.
8. Tokuda N, Kano M, Meiri H, et al. Calcitriol therapy modulates the cellular immune responses in hemodialysis patients. Am J Nephrol 2000; 20: 129.
9. Griffin MD, Lutz W, Phan VA, et al. Dendritic cell modulation by 1alpha, 25 dihydroxyvitamin D3 and its analogs: A vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro and in vivo. Proc Natl Acad Sci U S A 2001; 98: 6800.
10. Piemonti L, Monti P, Sironi M, et al. Vitamin D3 affects differentiation, maturation, and function of human monocyte-derived dendritic cells. J Immunol 2000; 164: 4443.
11. Clavreul A, D'Hellencourt CL, Montero-Menei C, et al. Vitamin D differentially regulates B7.1 and B7.2 expression on human peripheral blood monocytes. Immunology 1998; 95: 272.
12. Cantorna MT, Hayes CE, DeLuca HF. 1, 25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc Natl Acad Sci U S A 1996; 93: 7861.
13. Lemire JM, Ince A, Takashima M. 1, 25-Dihydroxyvitamin D3 attenuates the expression of experimental murine lupus of MRL/1 mice. Autoimmunity 1992; 12: 143.
14. Redaelli CA, Wagner M, Tien YH, et al. 1 alpha, 25-Dihydroxycholecalciferol reduces rejection and improves survival in rat liver allografts. Hepatology 2001; 34: 926.
15. Redaelli CA, Wagner M, Gunter-Duwe D, et al. 1 alpha, 25-dihydroxyvitamin D3 shows strong and additive immunomodulatory effects with cyclosporine A in rat renal allotransplants. Kidney Int 2002; 61: 288.
16. Hullett DA, Cantorna MT, Redaelli C, et al. Prolongation of allograft survival by 1, 25-dihydroxyvitamin D3. Transplantation 1998; 66: 824.
17. Cantorna MT, Hullett DA, Redaelli C, et al. 1, 25-Dihydroxyvitamin D3 prolongs graft survival without compromising host resistance to infection or bone mineral density. Transplantation 1998; 66: 828.
18. Kallio E, Hayry P, Pakkala S. MC1288, a vitamin D analogue, reduces short- and long-term renal allograft rejection in the rat. Transplant Proc 1996; 28: 3113.
19. Lewin E, Olgaard K. The in vivo effect of a new, in vitro, extremely potent vitamin D3 analog KH1060 on the suppression of renal allograft rejection in the rat. Calcif Tissue Int 1994; 54: 150.
20. Bertolini DL, Araujo PR, Silva RN, et al. Immunomodulatory effects of vitamin D analog KH1060 on an experimental skin transplantation model. Transplant Proc 1999; 31: 2998.
21. Linker-Israeli M, Elstner E, Klinenberg JR, et al. Vitamin D(3) and its synthetic analogs inhibit the spontaneous in vitro immunoglobulin production by SLE-derived PBMC. Clin Immunol 2001; 99: 82.
22. Dilworth FJ, Williams GR, Kissmeyer AM, et al. The vitamin D analog, KH1060, is rapidly degraded both in vivo and in vitro via several pathways: Principal metabolites generated retain significant biological activity. Endocrinology 1997; 138: 5485.
23. Aschenbrenner JK, Laeseke PF, Sollinger HW, et al. Oral 1, 25-(OH)2D3 modulates the progression of chronic allograft nephropathy by altering TGFbeta-1 signaling proteins. Am J Transplant 2001; 1(suppl 1): 245.
24. Aschenbrenner JK, Heisey DM, Sollinger HW. 1, 25-Dihydroxyvitamin D3 (1, 25-(OH)2D3) improves renal transplant function. J Am Soc Nephrol 2000; 11: 677A.
25. Massague JTG. F-beta signal transduction. Annu Rev Biochem 1998; 67: 753.
26. Yanagisawa J, Yanagi Y, Masuhiro Y, et al. Convergence of transforming growth factor-beta and vitamin D signaling pathways on SMAD transcriptional coactivators. Science 1999; 283: 1317.
27. Malin GJ AJ, Hullett DA, Becker BN. Vitamin D and rapamycin induce SMAD6 expression and alter TGF-beta production in renal epithelial cells. J Am Soc Nephrol 2000; 11: 666A.
28. Aschenbrenner JK, Sollinger HW, Becker BN, et al. 1, 25-(OH(2))D(3) alters the transforming growth factor beta signaling pathway in renal tissue. J Surg Res 2001; 100: 171.
29. Yanagi Y, Suzawa M, Kawabata M, et al. Positive and negative modulation of vitamin D receptor function by transforming growth factor-beta signaling through smad proteins. J Biol Chem 1999; 274: 12971.
30. Schwarz U, Amann K, Orth SR, et al. Effect of 1, 25 (OH)2 vitamin D3 on glomerulosclerosis in subtotally nephrectomized rats. Kidney Int 1998; 53: 1696.
31. Weinreich T, Merke J, Schonermark M, et al. Actions of 1, 25-dihydroxyvitamin D3 on human mesangial cells. Am J Kidney Dis 1991; 18: 359.
32. Abe H, Iehara N, Utsunomiya K, et al. A vitamin D analog regulates mesangial cell smooth muscle phenotypes in a transforming growth factor-beta type II receptor-mediated manner. J Biol Chem 1999; 274: 20874.
33. van Etten E, Branisteanu DD, Verstuyf A, et al. Analogs of 1, 25-dihydroxyvitamin D3 as dose-reducing agents for classical immunosuppressants. Transplantation 2000; 69: 1932.
34. Gregori S, Casorati M, Amuchastegui S, et al. Regulatory t cells induced by 1alpha, 25-dihydroxyvitamin d(3) and mycophenolate mofetil treatment mediate transplantation tolerance. J Immunol 2001; 167: 1945.